EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas

Tiina Vesterinen iD, Elina Peltola iD, Helena Leijon, Päivi Hannula iD, Heini Huhtala iD, Markus J Mäkinen, Lasse Nieminen, Elina Pirinen, Mikko Rönty, Mirva Söderström, Pia Jaatinen iD, Johanna Arola

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242015164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Tiina Vesterinen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, HUSLAB, HUS Diagnostic Center, Helsinki University Hospital, University of Helsinki, 00290 Helsinki, Finland. Hauptthemen laut MEDLINE: Insulinoma, Pancreatic Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Finnish Cancer Foundation, the Helsinki University Hospital Research Fund, the Hospital District of South Ostrobothnia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Insulinomas are rare functional pancreatic neuroendocrine tumours, which metastasize in 10% of cases. As predicting the prognosis can be challenging, there is a need for the determination of clinicopathological factors associated with metastatic potential. The aim of this study is to evaluate the glucagon-like peptide-1 receptor (GLP-1R) expression in insulinomas and to analyse its association with clinicopathological features and patient outcome. This retrospective study involves pancreatic tumour tissue samples from fifty-two insulinoma patients. After histological re-evaluation, formalin-fixed paraffin-embedded tissue samples were processed into tissue microarrays and stained immunohistochemically with a monoclonal GLP-1R antibody. Forty-eight of the forty-nine (98%) non-metastatic tumours expressed GLP-1R, while one non-metastatic, multiple endocrine neoplasia type 1 (MEN1)-related tumour and all three of the metastatic tumours lacked GLP-1R expression. The lack of GLP-1R expression was associated with impaired overall survival, larger tumour diameter, higher Ki-67 PI and weaker insulin staining. Somatostatin receptor 1–5 expression did not differ between GLP-1R-positive and GLP-1R-negative insulinomas. In conclusion, the lack of GLP-1R expression is associated with metastatic disease and impaired survival in insulinoma patients. Thus, GLP-1R expression could be a useful biomarker in estimating the metastatic potential of the tumour and the prognosis of surgically treated patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InsulinomaPancreatic NeoplasmsHumansAntibodies, MonoclonalGlucagon-Like Peptide-1 ReceptorInsulinRetrospective Studies

Stichwörter der Autor:innen

glucagon-like peptide-1 receptorsimmunohistochemistryinsulinomaneuroendocrine tumour

Substanzen

Antibodies, MonoclonalGlucagon-Like Peptide-1 ReceptorInsulinGLP1R protein, human

Autor:innen und Institutionen

  • Department of Pathology, HUSLAB, HUS Diagnostic Center, Helsinki University Hospital, University of Helsinki, 00290 Helsinki, Finland.
  • Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, 00290 Helsinki, Finland.
  • Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland.
  • Department of Internal Medicine, Tampere University Hospital, 33520 Tampere, Finland.
  • Endocrinology, Department of Internal Medicine, Tampere University Hospital, 33520 Tampere, Finland.
  • Faculty of Social Sciences, Tampere University, 33014 Tampere, Finland.

ORCID-Profile: Tiina Vesterinen, Elina Peltola, Päivi Hannula, Heini Huhtala, Pia Jaatinen

Förderung

  • the Finnish Cancer Foundation
  • the Helsinki University Hospital Research Fund
  • the Hospital District of South Ostrobothnia
  • Research Funding provided by Tampere University and the University Consortium of Seinäjoki
  • Research Funding provided by Tampere University Hospital
  • Finnish Cancer Foundation
  • Helsinki University Hospital Research Fund
  • Hospital District of South Ostrobothnia

Zitieren

APA

Vesterinen, T., Peltola, E., Leijon, H., Hannula, P., Huhtala, H., Mäkinen, M. J., Nieminen, L., Pirinen, E., Rönty, M., Söderström, M., Jaatinen, P., & Arola, J. (2023). Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242015164

Vancouver

Vesterinen T, Peltola E, Leijon H, Hannula P, Huhtala H, Mäkinen MJ, et al. Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242015164

BibTeX
@article{Vesterinen2023,
  author = {Vesterinen, Tiina and Peltola, Elina and Leijon, Helena and Hannula, Päivi and Huhtala, Heini and Mäkinen, Markus J and Nieminen, Lasse and Pirinen, Elina and Rönty, Mikko and Söderström, Mirva and Jaatinen, Pia and Arola, Johanna},
  title = {Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242015164}
}
Kostenlos starten →